Michael Gelband’s Cardlytics CDLX Stock Holding History

Michael Gelband’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,805	Closed	-$378K	–	1576
2024 Q3	$378K	Buy	+11,805	New	+$655K	﹤0.01%	1288
2024 Q2	–	Sell	-1,005	Closed	-$146K	–	1569
2024 Q1	$146K	Buy	+1,005	New	+$84.9K	﹤0.01%	1393
2022 Q4	–	Sell	-12,878	Closed	-$1.21M	–	1683
2022 Q3	$1.21M	Buy	12,878 +11,190	+663%	+$1.59M	0.02%	1029
2022 Q2	$377K	Buy	+1,688	New	+$565K	﹤0.01%	1448
2022 Q1	–	Sell	-621	Closed	-$411K	–	2231
2021 Q4	$411K	Buy	+621	New	+$475K	﹤0.01%	1519
2021 Q3	–	Sell	-378	Closed	-$480K	–	2163
2021 Q2	$480K	Buy	+378	New	+$427K	0.01%	1467
2020 Q2	–	Sell	-1,966	Closed	-$687K	–	1791
2020 Q1	$687K	Buy	+1,966	New	+$1.39M	0.04%	391
2019 Q2	–	Sell	-1,119	Closed	-$185K	–	1121
2019 Q1	$185K	Buy	+1,119	New	+$182K	0.01%	573

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $122M AUM 11.49% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's CDLX Position: Q4 2024 in Review

Michael Gelband sold out of Cardlytics (CDLX) in Q4 2024, closing a stake of 11,805 shares — an estimated $378K sold.

Michael Gelband first reported a position in CDLX in Q1 2019 and held it in 8 quarters. The position peaked at $1.21M in Q3 2022. 108 funds tracked by Wall St. Rank hold CDLX as of Q4 2024.

Michael Gelband reported no remaining Cardlytics position as of Q4 2024 after selling out during the quarter.
Michael Gelband sold 11,805 Cardlytics shares in Q4 2024, an estimated $378K.
Michael Gelband first reported a position in Cardlytics in Q1 2019 and held it in 8 quarters.
Michael Gelband's Cardlytics position peaked at $1.21M in Q3 2022.
108 funds tracked by Wall St. Rank held Cardlytics as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.